Forest and Merckle in osteoarthritis deal

FRX will develop and market in the U.S. ML3000, a small molecule to treat osteoarthritis, from Merckle (Blaubeuren, Germany). The product entered Phase III studies in Europe earlier this year. ML3000 ...